A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
書誌事項
- 公開日
- 2019-10
- 権利情報
-
- https://www.elsevier.com/tdm/userlicense/1.0/
- https://www.elsevier.com/legal/tdmrep-license
- DOI
-
- 10.1016/s2352-3026(19)30115-2
- 公開者
- Elsevier BV
この論文をさがす
収録刊行物
-
- The Lancet Haematology
-
The Lancet Haematology 6 (10), e521-e529, 2019-10
Elsevier BV